 BioLineRx Ltd. NASDAQ: BLRX TASE: BLRX, a clinical-stage biopharmaceutical company focused on oncology, today announced that the European Commission EC has granted Orphan Drug Designation to its lead oncology candidate, Motixafortide BL-8040, for the treatment of pancreatic cancer, based on a positive opinion from the Committee for Orphan Medicinal Products COMP of the European Medicines Agency EMA. Last year, Motixafortide received Orphan Drug Designation for the treatment of Pancreatic Cancer from the US Food and Drug Administration FDA. 